These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 31763792

  • 1. Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia.
    Zeijlemaker W, Kelder A, Cloos J, Schuurhuis GJ.
    Curr Protoc Cytom; 2019 Dec; 91(1):e66. PubMed ID: 31763792
    [Abstract] [Full Text] [Related]

  • 2. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
    Cloos J, Harris JR, Janssen JJWM, Kelder A, Huang F, Sijm G, Vonk M, Snel AN, Scheick JR, Scholten WJ, Carbaat-Ham J, Veldhuizen D, Hanekamp D, Oussoren-Brockhoff YJM, Kaspers GJL, Schuurhuis GJ, Sasser AK, Ossenkoppele G.
    J Vis Exp; 2018 Mar 05; (133):. PubMed ID: 29553571
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prognostic Impact and Phenotype of Residual Acute Myeloid Leukemia Stem Cells.
    Jaddaoui S, Bencharef H, Lamchahab M, Quessar A, Oukkache B.
    Clin Lab; 2022 Jun 01; 68(6):. PubMed ID: 35704721
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Leukemia-associated immunophenotypes subdivided in "categories of specificity" improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia.
    Rossi G, Giambra V, Minervini MM, De Waure C, Mancinelli S, Ciavarella M, Sinisi NP, Scalzulli PR, Carella AM, Cascavilla N.
    Cytometry B Clin Cytom; 2020 May 01; 98(3):216-225. PubMed ID: 31697027
    [Abstract] [Full Text] [Related]

  • 7. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
    Zhou Y, Moon A, Hoyle E, Fromm JR, Chen X, Soma L, Salipante SJ, Wood BL, Wu D.
    Cytometry B Clin Cytom; 2019 Jan 01; 96(1):67-72. PubMed ID: 30417521
    [Abstract] [Full Text] [Related]

  • 8. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia.
    Witte KE, Ahlers J, Schäfer I, André M, Kerst G, Scheel-Walter HG, Schwarze CP, Pfeiffer M, Lang P, Handgretinger R, Ebinger M.
    Pediatr Hematol Oncol; 2011 Mar 01; 28(2):91-9. PubMed ID: 21214408
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.
    Terwijn M, Zeijlemaker W, Kelder A, Rutten AP, Snel AN, Scholten WJ, Pabst T, Verhoef G, Löwenberg B, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ.
    PLoS One; 2014 Mar 01; 9(9):e107587. PubMed ID: 25244440
    [Abstract] [Full Text] [Related]

  • 12. A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia.
    Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, Morsberger L, Galkin S, Collector MI, Perkins B, Levis MJ, Griffin CA, Sharkis SJ, Borowitz MJ, Karp JE, Jones RJ.
    Blood; 2012 Apr 12; 119(15):3571-7. PubMed ID: 22262762
    [Abstract] [Full Text] [Related]

  • 13. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings.
    Cui W, Zhang D, Cunningham MT, Tilzer L.
    Int J Lab Hematol; 2014 Dec 12; 36(6):636-49. PubMed ID: 24602197
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Immunophenotypic characterization of leukemic stem cells in acute myeloid leukemia using single tube 10-colour panel by multiparametric flow cytometry: Deciphering the spectrum, complexity and immunophenotypic heterogeneity.
    Das N, Panda D, Gajendra S, Gupta R, Thakral D, Kaur G, Khan A, Singh VK, Vemprala A, Bakhshi S, Seth R, Sahoo RK, Sharma A, Rai S, Prajapati VK, Singh S.
    Int J Lab Hematol; 2024 Aug 12; 46(4):646-656. PubMed ID: 38456256
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
    Al-Mawali A, Gillis D, Lewis I.
    J Hematol Oncol; 2016 Jul 27; 9(1):61. PubMed ID: 27465508
    [Abstract] [Full Text] [Related]

  • 19. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
    Al-Mawali A, Gillis D, Lewis I.
    Am J Clin Pathol; 2009 Jan 27; 131(1):16-26. PubMed ID: 19095561
    [Abstract] [Full Text] [Related]

  • 20. Universal monitoring of minimal residual disease in acute myeloid leukemia.
    Coustan-Smith E, Song G, Shurtleff S, Yeoh AE, Chng WJ, Chen SP, Rubnitz JE, Pui CH, Downing JR, Campana D.
    JCI Insight; 2018 May 03; 3(9):. PubMed ID: 29720577
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.